Literature DB >> 34145213

Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer.

Xiaohui Zhang1, Fangyuan Li2, Yidong Zhou1, Feng Mao1, Yan Lin1, Songjie Shen1, Yuntao Li3, Sheng Zhang4, Qiang Sun5.   

Abstract

Long noncoding ribonucleic acids (LncRNAs) have been found to be involved in the proliferation, apoptosis, invasion, migration, and other pathological processes of triple-negative breast cancer (TNBC). Expression of the lncRNA actin filament-associated protein 1 antisense RNA1 (AFAP1-AS1) has been found to be significantly higher in TNBC than in other subtypes or in normal tissue samples, but the specific mechanism by which AFAP1-AS1 affects the occurrence and development of TNBC is yet to be revealed. In this study, we used Cell Counting Kit-8 (CCK-8), colony formation, wound healing migration, Transwell invasion, and nude mouse xenograft assays to confirm the role of AFAP1-AS1 in the proliferation, migration of TNBC cells in vitro and in vivo. In addition, we performed bioinformatics analyses, reverse transcriptase quantitative polymerase chain reaction (RT-qPCR), western blot (WB), and dual-luciferase reporter assays (dual-LRA) to confirm interaction among AFAP1-AS1, micro-RNA 2110 (miR-2110), and Sp1 transcription factor (Sp1). We found that silencing AFAP1-AS1 and Sp1 or upregulating miR-2110 suppressed the proliferation, migration, and invasion of MDA-MB-231 and MDA-MB-468 cells in vitro as well as tumor growth in vivo. Mechanistically, the dual-LRA highlighted that miR-2110 was an inhibitory target of AFAP1-AS1, and that AFAP1-AS1 functioned as a miR-2110 sponge to increase Sp1 expression. AFAP1-AS1 silencing led to a reduction in Sp1 mRNA and protein levels, which could be reversed by joint transfection with miR-2110 inhibitor. Our findings demonstrated that AFAP1-AS1 could modulate the progression of breast cancer cells and affect tumorigenesis in mice by acting as a miR-2110 sponge, resulting in regulation of Sp1 expression. Therefore, AFAP1-AS1 could play a pivotal role in the treatment of TNBC.

Entities:  

Year:  2021        PMID: 34145213     DOI: 10.1038/s41419-021-03917-z

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  2 in total

1.  Silencing of rhomboid domain containing 1 to inhibit the metastasis of human breast cancer cells in vitro.

Authors:  Chunjun Huang; Xiaochun Ji; Yinyin Peng; Minghua Wu; Weizhu Wu; Yong Luo; Gaoxiang Cheng; Ye Zhu
Journal:  Iran J Basic Med Sci       Date:  2018-11       Impact factor: 2.699

2.  Long noncoding RNA AFAP1-AS1 is upregulated in NSCLC and associated with lymph node metastasis and poor prognosis.

Authors:  Xuechun Leng; Xiangxiang Ding; Siwei Wang; Tian Fang; Wenrong Shen; Wenjia Xia; Ran You; Keping Xu; Rong Yin
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

  2 in total
  5 in total

Review 1.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

Review 2.  PCAT6 May Be a Whistler and Checkpoint Target for Precision Therapy in Human Cancers.

Authors:  Feng Jiang; Qiaoyi Lv; Cexun Hu; Zhanghui Li; Haojie Wu; Shujun Gao; Hui Wang; Yangjing Zhao; Qixiang Shao
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

Review 3.  A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer.

Authors:  Soudeh Ghafouri-Fard; Tayybeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Majid Mokhtari
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

4.  LINC00467 facilitates the proliferation, migration and invasion of glioma via promoting the expression of inositol hexakisphosphate kinase 2 by binding to miR-339-3p.

Authors:  Yin Zhang; Yaxuan Zhang; Sen Wang; Boqiang Cao; Daling Hu; Junli Jia; Yuhang Wang; Luyao Chen; Jiaming Li; Hongyi Liu; Huamin Tang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 6.832

5.  lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells.

Authors:  Zhiping Liu; Kaibing Hu; Xiang Wang; Youqian Zhang; Weiping Wang; Yindi Wu
Journal:  Open Med (Wars)       Date:  2022-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.